Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sacituzumab govitecan in combination with furmonertinib as second-line therapy for EGFR-mutant advanced/metastatic non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Fudan University | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING